Apnea of prematurity is a disorder in infants who are preterm that is defined as cessation of breathing (apnea) that lasts for more than 20 seconds and/or is accompanied by hypoxia or bradycardia. Apnea of prematurity is often linked to earlier prematurity (younger gestational age). [1]
| Apnea of prematurity | |
|---|---|
| Specialty | Pediatrics |
Apnea is traditionally classified as either obstructive, central, or mixed:
- Obstructive apnea may occur when the infant's neck is hyperflexed or conversely, hyperextended. It may also occur due to low pharyngeal muscle tone or to inflammation of the soft tissues, which can block the flow of air though the pharynx and vocal cords. [1]
- Central apnea occurs when there is a lack of respiratory effort. This may result from central nervous system immaturity, or from the effects of medications or illness. [1]
- Mixed apnea involves elements of both obstructive and central apnea. Many episodes of apnea of prematurity may start as either obstructive or central, but then involve elements of both, becoming mixed in nature.[1]
Over 50% of infants who are born preterm are estimated to be affected by apnea of prematurity.[2] Infants who are born weighing less than 1000g have close to a 100% risk of being affected by apnea of prematurity. Most premature infants are affected by 'central' apnea due to the developmental stage of their respiratory tract.[2]
Apnea of prematurity can increase the risk of chronic health conditions including retinopathy and increases the risk of problems with the infant's neurological development. Apnea lasting more than 60 seconds may result in death or disability.[2]
The main treatment for apnea of prematurity has been pharmaceutical treatment with methylxanthines that have a mechanism of action of bronchodilation and a stimulant of the respiratory system to promote spontaneous breathing. Caffeine, theophylline, and minophylline are the common medications used.
Pathophysiology
editVentilatory drive is primarily dependent on response to increased levels of carbon dioxide (CO2) and acid in the blood. A secondary stimulus is hypoxia. Responses to these stimuli are impaired in premature infants due to immaturity of specialized regions of the brain that sense these changes. In addition, premature infants have an exaggerated response to laryngeal stimulation (a normal reflex that closes the airway as a protective measure).[1]
Diagnosis
editApnea of prematurity can be readily identified from other forms of infant apnea such as obstructive apnea, hypoventilation syndromes, breathing regulation issues during feeding, and reflux associated apnea with an infant pneumogram or infant apnea/sleep study.
It has been reported that the incidence of neonatal apnea happens in almost all infants with gestational age of less than 29 weeks or the birth weight of less than 1000g.[3][4][5]
Treatment
editMedications
editMethylxanthines (theophylline and caffeine) have been used for almost three decades to treat apnea of prematurity.[6] These medications are thought to help by stimulating the preterm infant's respiratory drive, increasing activity of the diaphragm muscles, and by bronchodilation. There is some evidence that these medications can reduce to need for mechanical ventilation in preterm infants.[2] There is no clear evidence to determine which type of methylxanthine formulation is more effective for preterm infants.[2] The long term effects of this treatment approach has not been well studied. There is also not a lot of evidence to support the most effective way to treat very young preterm infants such as those who are born earlier than 28 weeks of gestational age.[2]
Respiratory support
editSimple tactile stimulation by touching the skin or patting the infant may stop an apneic episode by raising the infant's level of alertness. Increasing the environmental oxygen level by placing the infant in a tent or hood with supplemental oxygen can diminish the frequency of AOP, and may also help the infant maintain adequate oxygenation during short episodes of apnea. Increased oxygen at low levels can also be delivered using a nasal cannula, which additionally may provide some stimulation due to the tactile stimulation of the cannula. CPAP (continuous positive airway pressure) is sometimes used for apnea when medications and supplemental oxygen are not sufficient. Usually as a last resort, mechanical ventilation is used to support infants whose apnea cannot be controlled sufficiently by other methods and where the potential risk of harm from recurrent hypoxia is felt to outweigh the risks of injury from ventilation.
Monitoring
editIn-hospital monitors in the NICU typically measure respiratory movements, heartrate, and pulse oximetry. Central apnea can be detected quickly since it results in absence of respiratory movements. Obstructive apnea can be detected when the level of oxygen has declined in the blood and/or results in slowing of the heart rate.
Home apnea monitors (which must be distinguished from infant monitors that are designed only to allow parents to listen to the infant remotely) most frequently measure only respiratory movements and/or heart rate. They are generally used with premature infants who are otherwise ready for discharge, but who continue to require supplemental oxygen or medication for mild residual AOP. Home apnea monitoring is typically required for 6–12 weeks after discharge.
Outcome
editSince AOP is fundamentally a problem of the immaturity of the physiological systems of the premature infant, it is a self-limited condition that will resolve when these systems mature. It is unusual for an infant to continue to have significant problems with AOP beyond 43 weeks post-conceptual age.
Infants who have had AOP are at increased risk of recurrence of apnea in response to exposure to anesthetic agents, at least until around 52 weeks post-conceptual age.
There is no evidence that a history of AOP places an infant at increased risk for SIDS. However, any premature infant (regardless of whether they have had AOP) is at increased risk of SIDS. It is important that other factors related to SIDS risk be avoided (exposure to smoking, prone sleeping, excess bedding materials, etc.)
Epidemiology
editApnea of prematurity occurs in at least 85 percent of infants who are born at less than 34 weeks of gestation. The incidence is inversely related to the gestational maturity of the infant, but has considerable individual variability.
References
edit- ^ a b c d e Martin R.J.; et al. (2002). "Pathophysiologic Mechanisms Underlying Apnea of Prematurity". NeoReviews. 3 (4): e59–e65. doi:10.1542/neo.3-4-e59.
- ^ a b c d e f Moresco, Luca; Sjögren, Alice; Marques, Keri A; Soll, Roger; Bruschettini, Matteo (2023-10-04). Cochrane Neonatal Group (ed.). "Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants". Cochrane Database of Systematic Reviews. 2023 (10). doi:10.1002/14651858.CD015462.pub2. PMC 10548499. PMID 37791592.
- ^ Dong LB, Li YF, Zhang Y, Qiao S. A pilot study of limb stimulation for the treatment of neonatal apnea. Medicine (Baltimore). 2018;97(49):e12827. doi:10.1097/MD.0000000000012827.
- ^ Martin RJ, Abu-Shaweesh JM, Baird TM. Apnoea of prematurity.Paediatr Resp Rev 2004;5(suppl A):S377–82
- ^ Robertson CM, Watt MJ, Dinu IA. Outcomes for the extremelypremature infant: what is new? And where are we going. Pediatr Neurol2009;40:189–96.
- ^ Baird, T.M.; et al. (2002). "Clinical Associations, Treatment, and Outcome of Apnea of Prematurity". NeoReviews. 3 (4): e66–e70. doi:10.1542/neo.3-4-e66.